
Curis CRIS
$ 0.44
-6.38%
Curis Depreciation & Amortization | CRIS
Annual Depreciation & Amortization Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169 K | 203 K | 255 K | 233 K | 158 K | 144 K | 125 K | 177 K | 235 K | 193 K | 161 K | 155 K | 142 K | 127 K | 107 K | 686 K | 751 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 751 K | 107 K | 237 K |
Quarterly Depreciation & Amortization Curis
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 K | 8 K | 8 K | 36 K | 32 K | 42 K | 59 K | - | 61 K | 62 K | 64 K | 64 K | 63 K | 64 K | 64 K | 92 K | 61 K | 44 K | 36 K | 38 K | 36 K | 41 K | 43 K | 28 K | 52 K | 39 K | 25 K | 28 K | 30 K | 32 K | 35 K | 38 K | 40 K | 46 K | 53 K | 59 K | 63 K | 58 K | 55 K | 52 K | 51 K | 56 K | 34 K | 38 K | 41 K | 40.5 K | 41.5 K | 40.9 K | 39.2 K | 37.8 K | 37 K | 37.2 K | 36.6 K | 33.6 K | 34.2 K | 35.2 K | 31 K | 30.1 K | 30.4 K | 30.6 K | 31.7 K | 45.1 K | 21 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 92 K | 8 K | 42.2 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Vallon Pharmaceuticals
VLON
|
4 K | - | -6.47 % | $ 5.76 M | ||
|
Vaxart
VXRT
|
1.13 M | - | -25.06 % | $ 46.3 M | ||
|
XOMA Corporation
XOMA
|
2.96 M | - | - | $ 485 M | ||
|
Repare Therapeutics
RPTX
|
1.92 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
3.35 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
84 K | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
820 K | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
1.5 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
368 K | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
62.7 K | - | - | $ 13 M | ||
|
Lyra Therapeutics
LYRA
|
459 K | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-339 K | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
2.29 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
1.2 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
2.17 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
55.9 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1 K | - | -4.36 % | $ 27 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
228 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
5 K | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
44 K | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
412 K | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
295 K | - | - | $ 24.2 M | ||
|
Myovant Sciences Ltd.
MYOV
|
1.38 M | - | -0.04 % | $ 2.62 B | ||
|
Idera Pharmaceuticals
IDRA
|
100 K | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
1.06 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
19.4 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
94.5 K | - | - | $ 109 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
1.78 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
257 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
30 K | - | - | $ 591 K |